184 related articles for article (PubMed ID: 27105440)
21. 68Ga-DOTATATE Uptake in Pancreatic Metastasis of Renal Cell Carcinoma Mimicking Pancreatic Neuroendocrine Tumor.
Soydal C; Nak D; Araz M; Demirkazik A; Kucuk NO
Clin Nucl Med; 2019 Oct; 44(10):795-796. PubMed ID: 31306201
[TBL] [Abstract][Full Text] [Related]
22. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
23. A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation.
Rottenburger C; Papantoniou D; Mandair D; Caplin M; Navalkissoor S
Clin Nucl Med; 2018 Apr; 43(4):252-255. PubMed ID: 29432346
[TBL] [Abstract][Full Text] [Related]
24. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
Chan H; Moseley C; Zhang L; Bergsland EK; Pampaloni MH; Van Loon K; Hope TA
Pancreas; 2019 Aug; 48(7):948-952. PubMed ID: 31268975
[TBL] [Abstract][Full Text] [Related]
25. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
26. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
27. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
[TBL] [Abstract][Full Text] [Related]
28. The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges.
Raj N; Reidy-Lagunes D
Pancreas; 2018 Jan; 47(1):1-5. PubMed ID: 29232339
[No Abstract] [Full Text] [Related]
29. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Guenter R; Aweda T; Carmona Matos DM; Jang S; Whitt J; Cheng YQ; Liu XM; Chen H; Lapi SE; Jaskula-Sztul R
Surgery; 2020 Jan; 167(1):189-196. PubMed ID: 31629542
[TBL] [Abstract][Full Text] [Related]
30. Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III.
Hartmann H; Freudenberg R; Oehme L; Zöphel K; Schottelius M; Wester HJ; Wunderlich G; Kotzerke J; Brogsitter C
Nuklearmedizin; 2014; 53(5):211-6. PubMed ID: 25029274
[TBL] [Abstract][Full Text] [Related]
31. PET/CT Imaging of Unstable Carotid Plaque with
Wan MYS; Endozo R; Michopoulou S; Shortman R; Rodriguez-Justo M; Menezes L; Yusuf S; Richards T; Wild D; Waser B; Reubi JC; Groves A
J Nucl Med; 2017 May; 58(5):774-780. PubMed ID: 27932558
[No Abstract] [Full Text] [Related]
32. Value of the
Fastrez M; Artigas C; Sirtaine N; Wimana Z; Caillet M; Rozenberg S; Flamen P
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():69-74. PubMed ID: 28342392
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.
Ulaner GA; Bodei L
Clin Nucl Med; 2019 Apr; 44(4):330-331. PubMed ID: 30688738
[TBL] [Abstract][Full Text] [Related]
34. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
35. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
[TBL] [Abstract][Full Text] [Related]
36. Current Concepts in
Bodei L; Ambrosini V; Herrmann K; Modlin I
J Nucl Med; 2017 Nov; 58(11):1718-1726. PubMed ID: 28818983
[No Abstract] [Full Text] [Related]
37. Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors.
Treglia G; Farchione A; Stefanelli A; Brizi MG; Larghi A; Inzani F; Rindi G; Rufini V
Pancreas; 2013 May; 42(4):726-8. PubMed ID: 23591437
[No Abstract] [Full Text] [Related]
38. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
39. Pediatric applications of Dotatate: early diagnostic and therapeutic experience.
McElroy KM; Binkovitz LA; Trout AT; Czachowski MR; Seghers VJ; Lteif AN; States LJ
Pediatr Radiol; 2020 Jun; 50(7):882-897. PubMed ID: 32495176
[TBL] [Abstract][Full Text] [Related]
40. Choice Is Good at Times: The Emergence of [
Jha A; Patel M; Carrasquillo JA; Chen CC; Millo C; Maass-Moreno R; Ling A; Lin FI; Lechan RM; Hope TA; Taïeb D; Civelek AC; Pacak K
J Nucl Med; 2022 Sep; 63(9):1300-1301. PubMed ID: 35618479
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
